Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. HONA

Go back to Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range

Valeant Pharma (VRX) Outperforms Amid Broad Weakness

May 11, 2017 9:54 AM EDT

Valeant Pharma (NYSE: VRX) Outperforms Amid Broad Weakness

... More

Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M

May 9, 2017 7:05 AM EDT

Valeant Pharma (NYSE: VRX) reported GAAP Q1 EPS of $1.79, versus $1.08 reported last year. Revenue for the quarter came in at $2.11 billion, versus $2.37 billion reported last year.

Adjusted EBITDA (non-GAAP) of $861 Million

2017 Guidance

2017 Full Year Adjusted EBITDA (non-GAAP) in the range of $3.60 - $3.75... More